ERIS Stock Overview
Eris Lifesciences Limited, together with its subsidiaries, engages in the manufacture, marketing, and distribution of domestic branded formulations for chronic and sub-chronic therapies in India.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Eris Lifesciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹867.15 |
| 52 Week High | ₹971.90 |
| 52 Week Low | ₹602.00 |
| Beta | 0.41 |
| 1 Month Change | 2.51% |
| 3 Month Change | -2.94% |
| 1 Year Change | 39.96% |
| 3 Year Change | 45.98% |
| 5 Year Change | 38.49% |
| Change since IPO | 44.16% |
Recent News & Updates
An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14
Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Recent updates
An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Feb 24Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?
Dec 28Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today
Sep 23If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late
May 26Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 17Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?
Mar 12Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?
Feb 25Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar
Feb 12Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results
Jan 30
Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares
Jan 17Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay
Dec 30Is Eris Lifesciences Limited's (NSE:ERIS) Recent Performance Tethered To Its Attractive Financial Prospects?
Dec 10Eris Lifesciences (NSE:ERIS) Shareholders Booked A 25% Gain In The Last Year
Nov 23Is It Worth Buying Eris Lifesciences Limited (NSE:ERIS) For Its 1.1% Dividend Yield?
Oct 22How Does Eris Lifesciences' (NSE:ERIS) CEO Salary Compare to Peers?
Oct 01How Much Are Eris Lifesciences Limited (NSE:ERIS) Insiders Taking Off The Table?
Sep 14Investor Optimism Abounds Eris Lifesciences Limited (NSE:ERIS) But Growth Is Lacking
Aug 22Eris Lifesciences Limited (NSE:ERIS) Looks Interesting, And It's About To Pay A Dividend
Aug 08Should You Buy Eris Lifesciences Limited (NSE:ERIS) For Its Upcoming Dividend?
Aug 08Eris Lifesciences Limited's (NSE:ERIS) Risks Elevated At These Prices
Jul 28Shareholder Returns
| ERIS | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.5% | -2.8% | -1.5% |
| 1Y | 40.0% | 54.9% | 45.0% |
Return vs Industry: ERIS underperformed the Indian Pharmaceuticals industry which returned 54.9% over the past year.
Return vs Market: ERIS underperformed the Indian Market which returned 45% over the past year.
Price Volatility
| ERIS volatility | |
|---|---|
| ERIS Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: ERIS has not had significant price volatility in the past 3 months.
Volatility Over Time: ERIS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 3,548 | Amit Bakshi | www.eris.co.in |
Eris Lifesciences Limited, together with its subsidiaries, engages in the manufacture, marketing, and distribution of domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, anti-infective, blood related, cardiovascular, dermatology, gastrointestinal, gastroenterology, haematinics, hormones, nero/ central nervous system, neuropsychiatry, otologicals, pain/analgesics, respiratory, stomatologicals, cosmetology, women’s health, and vitamins/minerals/nutrients. It also provides patient care services, including blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and ante-natal care solutions.
Eris Lifesciences Limited Fundamentals Summary
| ERIS fundamental statistics | |
|---|---|
| Market cap | ₹117.97b |
| Earnings (TTM) | ₹3.86b |
| Revenue (TTM) | ₹18.41b |
30.5x
P/E Ratio6.4x
P/S RatioIs ERIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ERIS income statement (TTM) | |
|---|---|
| Revenue | ₹18.41b |
| Cost of Revenue | ₹3.44b |
| Gross Profit | ₹14.97b |
| Other Expenses | ₹11.11b |
| Earnings | ₹3.86b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 28.40 |
| Gross Margin | 81.33% |
| Net Profit Margin | 21.00% |
| Debt/Equity Ratio | 34.2% |
How did ERIS perform over the long term?
See historical performance and comparison